Aspiro Therapeutics retweeted
Let’s connect at @jpmorgan Week 2027!
I’m looking forward to returning to San Francisco, January 11 to 14, and connecting with investors, strategic partners, and colleagues across the life sciences community.
#JPMWEEK27 #JPM2027 #JPMWeek #biopartnering app.sosha.ai/s/qwBPhFqd
Aspiro Therapeutics retweeted
Why is CC16 attracting growing interest in respiratory research?
Looking forward to new findings being presented next week at #ERSCongress examining the relationship between CC16 and respiratory health in young adults.
#RespiratoryMedicine #Asthma #COPD
🤖 Made with AI
Aspiro Therapeutics retweeted
Looking forward to participating in #RESISanDiego and connecting with investors & strategic partners.
@AspiroTx is developing an inhaled peptidomimetic therapy that mimics the protective power of CC16.
Attending #RESISanDiego, let’s connect.
#biotech #COPD #ASthama @LSciNation
Aspiro Therapeutics retweeted
On #WorldAsthmaDay, we recognize the need to go beyond symptom control. Patients need therapies that address the disease, not just flare ups.
@AspiroTx We are working toward restoring lung function & preventing disease progression.
#AsthmaAwareness #RespiratoryHealth #Biotech
Aspiro Therapeutics retweeted
Heading to @atscommunity Respiratory Innovation Summit next month in Orlando.
We will be presenting new data showing a key step forward for our program, with a stable aerosol formulation enabling consistent delivery to the lung.
#ATS2026 #RIS2026 #Biotech
Aspiro Therapeutics retweeted
Excited to attend Investival Showcase March 10–11
@AspiroTx is developing an inhaled, disease-modifying therapy for asthma and COPD by mimicking the protective biology of CC16.
Meeting with investors to discuss early-stage therapeutic development.
#InvestivalUSA #Biotech
Aspiro Therapeutics retweeted
Joining ABD Capital Connect at #JPMWeek2026 to share Aspiro’s progress in respiratory innovation. In SF? Let’s connect.
@AspiroTx #copd #asthma #Biotech
Today we recognize the millions living with COPD, a leading cause of morbidity & mortality.
Up to 70% of adults with COPD remain undiagnosed
We’re developing a therapy to reduce inflammation, strengthen epithelial defenses, and modify disease progression💙
#WorldCOPDDay #COPD
🌍 World Lung Day 🌍
We stand with patients, caregivers, & all working toward healthier breathing for all. 💙
Aspiro Therapeutics is developing an inhaled CC16 therapy to reduce inflammation, strengthen defenses, and change the course of disease.
#WorldLungDay #COPD #Asthma
Early COPD is getting long overdue attention. This CNN piece highlights how lung damage can begin decades before diagnosis.
At Aspiro, we are developing an inhaled CC16-based therapy targeting these early pathways. @katiahetter @CNN
🔗 edition.cnn.com/2025/08/28/h…
We’re proud to share that Dr. Stefano Guerra and @Dr_Ledford Ledford, two of our co-founders, are contributing to NIH-funded research on CC16 and early COPD. Dr. Guerra leads the $3.8M NIAID study with Dr. Ledford as co-investigator. #COPD #NIH #Biotech
research.arizona.edu/news/38…
Aspiro Therapeutics retweeted
GSK’s $12B COPD deal highlights the value of first in class respiratory innovation. At @AspiroTx , we are developing a CC16 inspired inhaled therapy to modify disease in asthma and COPD, not just manage symptoms.
fiercebiotech.com/biotech/gs…
#biotech #COPD #asthma #respiratoryhealth
We’re excited to welcome @MattBritz and Dr. Anne Dixon as advisors to Aspiro! Matt brings deep biotech leadership, and Anne is a leading pulmonary expert. Their guidance will support our CC16-based approach for asthma and COPD.
🔗 buff.ly/y43uYui
#biotech #asthma #COPD
Excited to share that Aspiro Therapeutics has been selected to present at the #BIO2025 Startup Stadium in Boston!
@JamesLovgren will present our inhaled therapy inspired by CC16,
Join us Thurs, June 19. Let’s connect.
#StartupStadium #Biotech #COPD #Asthma #RespiratoryHealth
We’re just days away! Aspiro CEO @JamesLovgren will present at #RIS2025 this Saturday, May 17 at 2:00 PM PT.
Join us as we share our CC16-driven approach to transforming care for COPD & asthma. 🌬️
🔗 Agenda: conference.thoracic.org/prog…
#COPD #Asthma #Biotech #ATS2025
On #WorldAsthmaDay, we stand with millions living with asthma—and the urgent need for better care.
At Aspiro, we’re developing a therapy inspired by the body’s own defenses to restore lung function and prevent progression.
#asthma #CC16 #biotechforgood #WorldAsthmaDay2025
Excited to share that Aspiro CEO @JamesLovgren will present at #RIS2025 on Saturday, May 17 at 2:00 PM PT in San Francisco! We’re honored to be a Showcase Company advancing new solutions in #respiratoryhealth. 🌬️
Agenda: conference.thoracic.org/prog…
#ATS2025 #COPD #Asthma #Biotech
Aspiro Therapeutics is heading to #BIOCEO2025 next week in NYC! Our CEO, @JamesLovgren, will be connecting with investors & partners as we advance our mission to transform respiratory care. If you’re attending, let’s connect! #Biotech #RespiratoryHealth
Aspiro CEO @JamesLovgren is heading to the BIO CEO & Investor Conference 2025 (Feb 10–11 in NYC)! He’s excited to connect with partners & investors as we advance CC16-based therapies for COPD & asthma. Stay tuned for updates! 🌐 aspirotx.com/
#BIOCEO2025 #COPD #Asthma
🌟Thank you, #BiotechShowcase2025! @AspiroTx CEO @JamesLovgren shared how our CC16-inspired therapy is redefining care for #COPD & #asthma. Grateful for the enthusiastic response—excited to build on this momentum!
aspirotx.com
#COPD #Asthma #BiotechInnovation
















